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Benzene is an important industrial chem-
ical that is also present in gasoline, engine 
exhausts, wood smoke, and tobacco smoke 
[International Agency for Research on Cancer 
(IARC) 1989]. In fact, benzene is truly ubiq-
uitous in the environment, with air concen-
trations ranging from parts per billion in 
rural and urban settings to parts per million 
in some workplaces (IARC 1989; Wallace 
1996). This is worrisome because benzene 
causes leukemia and probably other lympho-
hematopoietic cancers in humans (Hayes et al. 
1997; Infante et al. 1977; Rinsky et al. 1987), 
and there is evidence that benzene is hema-
totoxic at levels < 1 ppm (3.2 mg/m3) (Lan 
et al. 2004), the current permissible expo-
sure limit in the United States (Occupational 
Safety and Health Administration 1987). 
Benzene also produces malignant tumors at 
multiple sites in rodents (Huff et al. 1989; 
Maltoni et al. 1989).
The toxicology of few chemicals has been 
pursued as vigorously as that of benzene. A 
PubMed search of the keywords “benzene” 
and “toxicity” returned more than 2,700 
publications. Reports of benzene’s propen-
sity to damage human blood-forming tissues 
emerged as early as 1897 (Santesson 1897), 
and the first evidence of its leukemoge-
nicity was published in 1928 (Delore and 
Borgomano 1928).
Although benzene must be metabolized 
to exert toxicity, the metabolism is complex, 
and particular roles played by the various 
metabolites have not been fully elucidated 
(Ross 1996; Smith 1996; Snyder 2002). As 
shown in Figure 1, benzene is oxidized by 
cytochrome P450 (CYP) enzymes to benzene 
oxide, which exists in equilibrium with its tau-
tomer oxepin. Spontaneous rearrangement of 
benzene oxide produces phenol that is either 
excreted or oxidized by CYP enzymes to hyd-
roquinone, which is excreted or oxidized to 
1,4-benzoquinone. Other major metabolites 
include catechol (which can be oxidized to 
1,2-benzoquinone), after hydrolysis of ben-
zene oxide and aromatization of benzene 
dihydrodiol, and E,E-muconic acid (hereafter 
“muconic acid”), after oxidation of oxepin 
and ring opening. Reaction between benzene 
oxide and glutathione, possibly mediated by 
glutathione-S-transferases, can produce the 
minor metabolite S-phenylmercapturic acid 
(SPMA). For humans exposed to benzene at 
air concentrations between 0.1 and 10 ppm, 
phenol represents 70–85% of urinary ben-
zene metabolites, whereas hydroquinone, 
muconic acid, and catechol each represent 
5–10%, and SPMA represents less than 1% 
(Kim et al. 2006b).
Benzene oxide, the benzoquinones, 
muconaldehydes, and benzene diol epoxides 
(formed from CYP oxidation of benzene dihy-
drodiol) are electrophiles that readily react 
with peptides and proteins (Bechtold et al. 
1992; Henderson et al. 2005; McDonald 
et al. 1993; Waidyanatha et al. 2005) and can 
thereby interfere with cellular function (Smith 
1996). Reactions between 1,4-benzoquinone 
and critical nucleophilic loci in topoisomerase 
II, an important enzyme involved in DNA 
replication and maintenance, are men-
tioned as likely key events in the cascade of 
effects related to benzene’s ability to damage 
chromosomes (Chen and Eastmond 1995; 
Lindsey et al. 2004).
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Background: Recent evidence has shown that humans metabolize benzene more efficiently at 
environmental air concentrations than at concentrations > 1 ppm. This led us to speculate that an 
unidentified metabolic pathway was mainly responsible for benzene metabolism at ambient levels.
oBjective: We statistically tested whether human metabolism of benzene is better fitted by a 
kinetic model having two pathways rather than one.
Methods: We fit Michaelis-Menten-like models to levels of urinary benzene metabolites and the 
corresponding air concentrations for 263 nonsmoking Chinese females. Estimated benzene con-
centrations ranged from less than 0.001 ppm to 299 ppm, with 10th and 90th percentile values of 
0.002 ppm and 8.97 ppm, respectively.
results: Using values of Akaike’s information criterion obtained under the two models, we found 
strong statistical evidence favoring two metabolic pathways, with respective affinities (benzene air 
concentrations analogous to Km values) of 301 ppm for the low-affinity pathway (probably domi-
nated by cytochrome P450 enzyme 2E1) and 0.594 ppm for the high-affinity pathway (unknown). 
The exposure-specific metabolite level predicted by our two-pathway model at nonsaturating con-
centrations was 184 µM/ppm of benzene, a value close to an independent estimate of 194 µM/ppm 
for a typical nonsmoking Chinese female. Our results indicate that a nonsmoking woman would 
metabolize about three times more benzene from the ambient environment under the two-pathway 
model (184 µM/ppm) than under the one-pathway model (68.6 µM/ppm). In fact, 73% of the 
ambient benzene dose would be metabolized via the unidentified high-affinity pathway.
conclusion: Because regulatory risk assessments have assumed nonsaturating metabolism of ben-
zene in persons exposed to air concentrations well above 10 ppm, our findings suggest that the true 
leukemia risks could be substantially greater than currently thought at ambient levels of exposure—
about 3-fold higher among nonsmoking females in the general population.
key words: benzene, biomonitoring, cancer risk, cytochrome P450, metabolism. Environ Health 
Perspect 117:946–952 (2009). doi:10.1289/ehp.0800510 available via http://dx.doi.org/  [Online 
19 February 2009]
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Although there is undoubtedly a causal 
link between benzene exposure and leukemia, 
the shape of the exposure–response relation-
ship is controversial, particularly at low doses. 
Indeed, when considering regulatory actions, 
litigation, and potential cleanup costs in the 
billions of dollars, this uncertainty represents 
a major challenge for environmental toxicol-
ogy and epidemiology. Recent action by the 
U.S. Environmental Protection Agency (EPA) 
to reduce cancer risks from mobile sources 
underscores this point (U.S. EPA 2007). In 
justifying its decision to lower the benzene 
content of gasoline, the U.S. EPA cited stud-
ies pointing to supralinear (greater-than-
proportional) production of benzene-related 
protein adducts at air concentrations < 1 ppm 
(Rappaport et al. 2002, 2005). Such behav-
ior would likely result from saturation of the 
metabolism of benzene to benzene oxide/
oxepin. Because the U.S. EPA had previously 
assumed that human benzene metabolism 
proceeded according to nonsaturating (first-
order) kinetics at exposure concentrations 
well above 10 ppm, saturation of metabo-
lism below 1 ppm “could lead to substan-
tial underestimation of leukemia risks” in the 
general population (U.S. EPA 2007).
Because the dose-related metabolism of 
benzene had been poorly characterized in 
humans, we conducted a detailed investiga-
tion of urinary metabolite levels among 386 
workers in Tianjin, China, for whom indi-
vidual levels of benzene in air had been docu-
mented on the days of urine collection (Kim 
et al. 2006a). We observed that metabolite 
levels were significantly affected by benzene 
exposure as well as sex, age, smoking, sin-
gle nucleotide polymorphisms of prominent 
metabolizing genes, and gene–environment 
and gene–smoking interactions (Kim et al. 
2006b, 2007). Intriguingly, the exposure-spe-
cific production of major metabolites (phenol, 
muconic acid, hydroquinone, and catechol, in 
micromolar per parts per million benzene) 
decreased continuously with estimated expo-
sure levels over the range of 0.03–88.9 ppm, 
with the most pronounced decreases occur-
ring at benzene concentrations < 1 ppm (Kim 
et al. 2006a).
Given the unanticipated decline in expo-
sure-specific metabolism at air concentrations 
< 1 ppm, we speculated that benzene metab-
olism might be governed by two saturable 
pathways, one operating primarily > 1 ppm, 
and the other primarily at lower concentra-
tions. To test this conjecture, we combined 
exposure and urinary metabolite data from 
two studies of Chinese workers, representing 
428 subjects exposed to benzene at estimated 
levels ranging from < 0.001 ppm to > 300 
ppm (Kim et al. 2006a; Waidyanatha et al. 
2004). Because sex and smoking had previ-
ously been shown to affect benzene metabolite 
levels at a given exposure concentration in 
this population, we restricted our analyses to 
263 nonsmoking females with valid data (esti-
mated benzene exposure range, < 0.001–299 
ppm; we removed one previously identified 
outlier). Because metabolic processes follow 
saturable (Michaelis-Menten) kinetics, we fit 
Michaelis-Menten-like models to the molar 
levels of urinary benzene metabolites (the sum 
of phenol, muconic acid, hydroquinone, cat-
echol, and SPMA) in these subjects and used 
statistical fit criteria derived from information 
theory to weigh the evidence favoring the two 
models. Our results provide strong statistical 
evidence favoring two saturable pathways, 
one operating primarily at concentrations < 1 
ppm and the other primarily at concentra-
tions > 1 ppm.
Materials and Methods
Study population and air and biological 
monitoring. Study subjects derive from two 
cross-sectional molecular epidemiology stud-
ies of Chinese benzene-exposed and control 
workers carried out in Shanghai in 1992 
(Rothman et al. 1996, 1998; Waidyanatha 
et al. 2004) and in Tianjin in 2000–2001 
(Kim et al. 2006a; Lan et al. 2004; Vermeulen 
et al. 2004). Subject enrollment and interview 
procedures, exposure assessment methods, and 
urinary metabolite measurements in these two 
studies were carried out by the same group of 
investigators using the same procedures. All 
subjects gave informed written consent to act 
as human subjects, and all applicable approv-
als were obtained. Workers with occupational 
exposure to benzene were employed in facto-
ries where benzene was present, and control 
workers were exposed to airborne benzene in 
the general environment, as determined by 
measurement of urinary benzene (Tianjin con-
trols only) (Kim et al. 2006a). Among non-
smoking females, 159 benzene-exposed and 
84 control subjects had complete data. Table 1 
shows summary statistics regarding benzene 
exposure, age, body mass index, and weight.
The methods of sampling air and urine 
have been reported previously (Kim et al. 
2006a; Lan et al. 2004; Vermeulen et al. 
2004; Waidyanatha et al. 2001). Briefly, we 
matched personal full-shift air measurements 
with postshift urine samples from exposed 
and control workers. Statistical analyses used 
the sum of the molar concentrations of phe-
nol, hydroquinone, catechol, muconic acid, 
and SPMA (hereafter “total metabolites”). 
Three subjects were missing measurements 
of SPMA. Because SPMA rarely exceeds 1% 
of total metabolites, we estimated levels of 
total metabolites for these three subjects as 
the sum of phenol, hydroquinone, catechol, 
and muconic acid. Of the 263 subjects in this 
Figure 1. Simplified metabolic scheme for benzene showing major pathways and metabolizing genes. 
GST, glutathione-S-transferase; NQO1, NAD(P)H:quinone oxidoreductase 1; MPO, myeloperoxidase; 
CYP2E1, cytochrome P450 2E1.
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Table 1. Summary statistics for the study population (nonsmoking female subjects, n = 263).
Statistic Median value (range) 10th–90th percentiles
Benzene exposure (ppm) 0.644 (1.5 × 10–4 to 299) 0.002–8.97
Age (years) 32 (18–52) 21–44
Body mass index (kg/m2) 21.8 (15.4–38.2) 18.5–26.7
Weight (kg) 57 (39–96) 48–70
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analysis, 243 had repeated measurements of 
air and urine, making a total of 391 matched 
air/urine samples. Subjects with repeated mea-
surements had a median of three paired air 
and urine samples (range, 2–4).
Benzene was measured in air using passive 
personal monitors (Organic Vapor Monitors, 
model 3500; 3M, St. Paul, MN, USA) fol-
lowed by solvent desorption and gas chroma-
tography (GC) with flame ionization detection 
(Vermeulen et al. 2004). A total of 161 air 
measurements were either missing or below 
the limit of detection (normally 0.2 ppm). We 
predicted air concentrations for these censored 
and missing air samples from the correspond-
ing levels of urinary benzene, as described 
previously (Kim et al. 2006a). The estimated 
median exposure to benzene among the non-
smoking female subjects was 0.644 ppm, with 
10th and 90th percentile values of 0.002 ppm 
and 8.97 ppm, respectively (Table 1).
We determined urinary benzene by 
GC-mass spectrometry (MS) using head-space 
solid-phase microextraction according to the 
method of Waidyanatha et al. (2001). Urinary 
phenol, hydroquinone, catechol, muconic 
acid, and SPMA were measured as trimethyl-
silyl derivatives by GC-MS, after acid hydro-
lysis of urine to release conjugates, according 
to Waidyanatha et al. (2004). Quantification 
of all urinary analytes was based on peak areas 
relative to the corresponding isotopically 
labeled internal standards.
The Shanghai workers were exposed to 
essentially pure benzene, whereas all Tianjin 
workers were coexposed to toluene, and some 
were exposed to low levels (< 5 ppm) of other 
volatile organic compounds (Vermeulen et al. 
2004). We previously found no significant 
effects of toluene coexposure on levels of ben-
zene metabolites in the Tianjin workers (Kim 
et al. 2006b).
Michaelis-Menten-like models. We 
examined relationships between levels of 
total metabolites and the corresponding air 
concentrations of benzene using nonlinear 
regression models (implemented with the 
SAS procedure NLIN; SAS Institute Inc., 
Cary, NC, USA). To consider saturable 
metabolism, we invoked Michaelis-Menten-
like models, where the enzymatic velocity (v) 
was replaced with the level of total metab-
olites (Y) (micromolar), and the substrate 
concentration with the air concentration of 
benzene (X) (parts per million). The asymp-
totically maximum level of Y (designated 
Ymax) is analogous to vmax, and the benzene 
concentration X at which Y = Ymax/2 (des-
ignated X50, in parts per million) is analo-
gous to Km. We also assumed a background 
level of total metabolites Y0 (micromolar) 
due to endogenous and dietary sources of 
the individual compounds, particularly phe-
nol, hydroquinone, and catechol (Kim et al. 
2006a; McDonald et al. 2001). Given our 
hypothesis that two saturable pathways gov-
erned benzene metabolism rather than one, 
we fit two Michaelis-Menten-like models to 
the data, one having a single metabolic path-
way and the other having two pathways that 
competed for access to benzene (X). The fol-
lowing expressions define the two models:
 
ln(Y ) = ln Y0 +
Ymax × X
X 50+X( ), [1]
 
ln(Y )= ln Y0 +
Ymax,1× X
X 50,1+X
+
Ymax,2 × X
X 50,2+X( ), [2]
where the subscripts 1 and 2 in Equation 2 refer 
to the first and second metabolic pathways, 
respectively. We will refer to Equation 1 as the 
“one-pathway model” and to Equation 2 as the 
“two-pathway model.” Also, because the affinity 
of a given enzyme pathway is indicated by X50 
(the benzene air concentration at which Y is 
half-maximal, analogous to Km), we define path-
way 1 as the low-affinity pathway and pathway 
2 as the high-affinity pathway, which is to say 
that X50,2 < X50,1.
Each data pair (Y, X) represents the post-
shift total metabolite concentration and the 
corresponding full-shift benzene air concen-
tration for a given subject. For subjects with 
repeated measurements (n = 243), we used 
estimated geometric means of air and total 
metabolite levels. Given the highly skewed and 
heteroskedastic levels of benzene in air and 
total metabolites, natural log transforms of Y 
and the independent variables were used for 
regression analyses. Initial values for Y0, Ymax, 
X50, Ymax,1, and X50,1 were estimated from 
scatter plots of benzene metabolite levels versus 
benzene exposure. Because we defined meta-
bolic pathway 2 as having higher affinity and 
lower capacity than metabolic pathway 1, we 
assigned initial values to Ymax,2 << Ymax,1 and 
to X50,2 << X50,1. However, the final model 
was not sensitive to initial values of these 
parameters. The estimated kinetic parameters 
were used to construct overall profiles and 
partial profiles for the one-pathway and two-
pathway models. Uncertainties in the parame-
ters estimated under Equation 1 and Equation 
2 were evaluated via bootstrap resampling with 
replacement (n = 1,000, implemented with 
the SAS macro %boot). We used bootstrap 
results to estimate median, 2.5th, and 97.5th 
percentile values for each kinetic parameter 
in Equations 1 and 2 as well as the ratios 
Ymax,1:X50,1 and Ymax,2:X50,2, which represent 
maximum rates of metabolism (micromole per 
parts per million) for the two pathways (analo-
gous to vmax/Km), respectively.
Weights of evidence for models. In judg-
ing the weight of evidence favoring either the 
one-pathway model or two-pathway model 
as a depiction of the true metabolism for 
benzene (i.e., “truth”), we employed criteria 
derived from information theory that offer 
advantages over hypothesis testing in selecting 
among candidate models derived from scien-
tific considerations (Burnham and Anderson 
Figure 2. Scatterplot of levels of total metabolites versus the level of benzene in air for 263 nonsmoking 
female subjects. Open data points represent subjects from Tianjin, and solid points represent subjects 
from Shanghai. The dashed curve represents the benzene metabolite level predicted under the one-
pathway model (Equation 1), and the solid curve represents the benzene metabolite level predicted under 
the two-pathway model (Equation 2).
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2002). Because the models represented by 
Equations 1 and 2 are nested, and the number 
of observations (n = 263) exceeds 40 times the 
number of model parameters (three or five), 
Akaike’s information criterion (AIC) provides 
an appropriate means for judging the better 
fit; that is, the model with the smaller AIC 
is better. The difference in AIC values (∆i) 
between the ith model and the best model 
and the associated Akaike weights, 
  
wi =
exp − 1
2
Δ i( )
exp − 1
2
Δ i( )
i=l
r
∑
⎛
⎝
⎜
⎜
⎜
⎞
⎠
⎟
⎟
⎟
, [3]
(where r is the number of models for compar-
ison; r = 2 here) provide information about 
the weights of evidence supporting the com-
peting models. By definition, the best model 
(i.e., the one with the smallest AIC) has a 
value of ∆min = 0. Therefore, wi varies between 
exp(–∆i/2) and 1 and represents the odds that 
the ith model is, in fact, the best depiction of 
truth, given the available data. Thus, a model 
having wi > 0.9 offers a compelling depiction 
of truth with the data at hand, and a model 
with wi < 0.1 offers a poor depiction of truth 
(Burnham and Anderson 2002).
All statistical analyses were performed using 
SAS software for Windows version 9.13 (SAS).
Results
Figure 2 shows a scatterplot of total metabo-
lite levels for the 263 subjects versus the shift-
long air concentration of benzene on the day 
of urine collection. At benzene concentrations 
< 0.1 ppm, the data primarily reflect back-
ground sources of the metabolites. The effect 
of benzene exposure on metabolite production 
becomes increasingly apparent at air concentra-
tions > 1 ppm, and at levels > 100 ppm there is 
evidence that metabolite levels are approaching 
a plateau. There is a roughly 5-fold range of 
metabolite levels among nonsmoking females 
at a given air concentration of benzene.
Estimated parameters for the Michaelis-
Menten-like models. Also shown in Figure 
2 are the mean trends for metabolite levels 
predicted from the parameters of the one-
pathway model (dashed curve) and the two-
pathway model (solid curve). Although both 
models offer qualitatively similar fits to the 
data in log scale, there are important quan-
titative differences, as shown by the esti-
mated parameters in Table 2 and the ratios 
Ymax,1:X50,1 and Ymax,2:X50,2. Thus, the ques-
tion of which model provides a better fit to 
the data is extremely important. Because the 
AIC values were –313.755 for the one-path-
way model (Equation 1) and –319.320 for 
the two-pathway model (Equation 2), result-
ing in a difference of –313.755 – (–319.320) 
= 5.473, we conclude that the two-pathway 
model provides a much better fit to the data. 
(Note that the weight of evidence supporting 
the two-pathway model depends strictly upon 
the difference in AIC values between the two 
models rather than the relative magnitudes of 
the AIC values under the two models.) This 
conclusion is supported by the Akaike weights 
of w1 = 0.061 and w2 = 0.939 for the one-
pathway and two- pathway models, respec-
tively, which indicate that, given the available 
data, Equation 2 offers a statistically robust 
depiction of the true benzene metabolism.
Table 2 also summarizes results from 
bootstrap resampling of the data under the 
one-pathway and two-pathway models. In 
both cases, the medians of the bootstrap real-
izations are very similar to the parameters 
estimated by the original models. The uncer-
tainties in parameter estimates are indicated 
by the range between the 2.5th and 97.5th 
percentile values from the 1,000 bootstrap 
samples in each case.
To visualize predicted metabolite lev-
els free of background effects, the curves in 
Figure 3 represent the background-adjusted 
benzene metabolite levels, given by ( Yˆx–Yˆ0) 
where Yˆx and Yˆ0 represent the predicted levels 
of benzene metabolites at benzene concentra-
tions X and 0 ppm, respectively, using the 
estimated parameters from Equation 1 (blue 
curve) and Equation 2 (black curve) from 
the original regressions (Table 2). Metabolite 
levels predicted from the two models are 
similar for benzene exposures in the range of 
3–100 ppm but differ substantially for lower 
exposure concentrations.
Exposure-specific metabolism of ben-
zene at parts per billion exposure levels. The 
surrogate for the maximum metabolic rate 
of benzene (vmax/Km) in our analyses is the 
exposure-specific level of benzene metabolites 
(micromolar per parts per million) produced 
at nonsaturating (parts per billion) air con-
centrations. Under the one-pathway model 
(Equation 1), this exposure-specific metabo-
lite level would be Ymax/X50 = 68.6 µM/
ppm, whereas under the two-pathway model 
(Equation 2) it would be the sum Ymax,1/X50,1 
= 48.7 µM/ppm plus Ymax,2/X50,2 = 135 µM/
ppm, or 184 µM/ppm (Table 2).
Based on AIC values given above, the fit of 
the two-pathway model was superior to that of 
the one-pathway model. Thus, we sought inde-
pendent confirmation that the exposure-specific 
Figure 3. Predicted contributions of two metabolic pathways toward production of total metabolites at dif-
ferent levels of benzene exposure. (A) Predicted mean trend (metabolic pathway 1 + metabolic pathway 2) 
and partial trends (metabolic pathway 1 or metabolic pathway 2) representing background-adjusted levels 
of benzene metabolites for a typical nonsmoking female subject. Predictions were based on parameters 
estimated for the two-pathway model (Equation 2) from the original regression (see Table 2). (B) Predicted 
percentages of benzene metabolites from the trends shown in (A) for the individual metabolic pathways.
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Table 2. Parameter estimates for models of benzene metabolites (corresponding to Equations 1 and 2) for 
263 nonsmoking female subjects. 
   Bootstrap resampling (n = 1,000)
  Original model  2.5th, 97.5th  
Model Parameter estimate (SE) Median percentiles
One pathway (Equation 1) Y0 (µM)  94.64 (4.774) 94.68 85.76, 104.1
 Ymax (µM) 8,253 (2,877) 8,252 4,602, 15,169
 X50 (ppm) 120.3 (47.49) 119.7 58.76, 251.6
 Ymax:X50 (µM/ppm) 68.60 69.08 56.01, 84.84
Two pathways (Equation 2) Y0 (µM) 87.20 (5.244) 86.30 60.13, 95.94
 Ymax,1 (µM) 14,637 (10,321) 14,742 7,554, 60,992
 X50,1 (ppm) 300.6 (260.6) 301.2 121.5, 1,743
 Ymax,2 (µM) 80.06 (67.26) 77.75 32.17, 209.6
 X50,2 (ppm) 0.5938 (0.9616) 0.5756 0.0030, 2.765
 Ymax,1:X50,1 (µM/ppm) 48.69 48.91 32.98, 68.23
 Ymax,2:X50,2 (µM/ppm) 134.8 142.7 45.84, 18,672
Abbreviations: Y, level of total metabolites (µM), X, benzene air concentration (ppm); Y0, background level of Y; Ymax,i, 
maximum value of Y given the ith metabolic pathway; X50,i, X corresponding to 50% of Ymax,i.
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metabolite level predicted under Equation 2 
(184 µM/ppm) was, indeed, more reasonable 
than that from Equation 1 (68.6 µM/ppm) 
at parts per billion levels of exposure. In order 
to estimate metabolite levels for a typical non-
smoking Chinese female exposed to benzene at 
parts per billion levels, information is required 
regarding the rates of inhalation and urine pro-
duction and the fractions of the inhaled dose 
retained in the lung and excreted as urinary 
metabolites. The first two pieces of informa-
tion are relatively straightforward because a 
typical Chinese female working at light exercise 
should have a breathing rate of 0.863 m3/hr 
(Yu et al. 2001) and should produce 63.8 mL 
of urine per hour (Fitzgerald and Brubaker 
2003). However, lung retention of benzene at 
parts per billion exposure levels is less obvious 
because relatively few studies have reported 
both inhaled and exhaled breath concentrations 
of benzene among persons exposed at parts 
per billion levels. Based on the original data 
from another study conducted in our labora-
tory among 19 nonsmoking garage mechanics 
(Egeghy et al. 2002), we estimated a median 
value of 73% lung retention of benzene (range, 
45–86%) based on geometric mean inhaled air 
(range, 7–204 ppb) and breath concentrations 
(range, 1.9–54.6 ppb) for three independent 
measurements per subject (breath levels were 
measured immediately after 4-hr personal 
measurements of inhaled air). Regarding the 
fractional excretion of benzene metabolites 
at parts per billion levels (free of background 
effects), we relied upon the estimated median 
excretion value of 48% among four subjects 
experimentally exposed to 40 ppb 13C-benzene 
for 2 hr (Weisel et al. 2003). Using these val-
ues, the exposure- specific metabolite level for 
a typical nonsmoking female exposed to ben-
zene for several hours at parts per billion levels 
should be
3.19 mg/m3
ppm
×
0.863 m3
h
×
h
63.8 mL
×
103 mL
L
×
mmol
78.1 mg
×
103 µmol
mmol
× 0.73 × 0.48
=
194 µ
.
M
ppm  [4]
Clearly, this value of 194 µM/ppm 
(Equation 4) is similar to that of 184 µM/ppm 
predicted under our two-pathway model and 
is substantially larger than that of 68.6 µM/
ppm predicted under our one-pathway model.
Percentages of benzene metabolized by the 
two pathways. The two solid curves in Figure 
3A represent the background-adjusted partial 
metabolite trends corresponding to the two 
metabolic pathways, again based on the origi-
nal regression. These partial trends indicate 
that pathway 1 began to saturate at a benzene 
concentration of about 200 ppm, and that 
pathway 2 began to saturate at concentra-
tions < 0.1 ppm and was near full saturation 
at 1 ppm. Figure 3B shows relative percent-
ages of benzene metabolites attributable to 
the two metabolic pathways at increasing 
levels of benzene exposure. At air concen-
trations < 0.04 ppm, about 73% of ben-
zene metabolites derived from pathway 2. 
As the benzene concentration increased, the 
proportion of benzene metabolites derived 
from pathway 2 dropped to 50% at about 
1 ppm and to 10% at about 12 ppm. Above 
12 ppm, pathway 1 accounted for virtually 
all metabolism of benzene.
Discussion
We previously used regression splines to 
characterize nonlinear relationships between 
levels of individual benzene metabolites and 
air exposures in 386 Chinese workers (Kim 
et al. 2006b, 2007). Although spline models 
offered useful basis functions for evaluating 
the effects of physiologic, lifestyle, and genetic 
factors upon benzene metabolism, they shed 
little light on the underlying toxicokinetics, 
other than to suggest some inconsistency with 
the notion that benzene was metabolized by a 
single saturable pathway. This led us to ques-
tion whether an unrecognized high-affinity/
low-capacity pathway might contribute sub-
stantially to human benzene metabolism at air 
concentrations < 1 ppm. Previous investiga-
tors noted dose-related differences in excretion 
patterns of muconic acid and/or hydroqui-
none between rats and mice (Medinsky et al. 
1989, 1996; Sabourin et al. 1989) and 
between strains of mice (Witz et al. 1990), 
which they attributed variously to competi-
tion across benzene and its metabolites for 
the same enzymes, competition across phase 
I and phase II pathways for elimination of 
individual metabolites, and different activities 
of benzene-metabolizing enzymes across spe-
cies or strains. Also, Yu and Weisel (1996a, 
1996b) noted that humans exposed to sub-
parts per million levels of benzene absorbed 
significantly larger doses and excreted larger 
proportions of the absorbed dose as muconic 
acid than did those exposed at parts per mil-
lion levels. However, to our knowledge no 
one has previously suggested that dose-related 
behavior might arise, at least in part, from the 
presence of two benzene-metabolizing path-
ways having vastly different affinities.
To determine whether human benzene 
metabolism involves two saturable path-
ways, we examined the fits of two Michaelis-
Menten-like models (Equations 1 and 2) 
with air and total metabolite data from 263 
nonsmoking female subjects, exposed to esti-
mated benzene air concentrations ranging 
from < 1 ppb to 299 ppm. Because we wished 
to model the quantitative metabolism of ben-
zene per se, we focused on total metabolites 
rather than individual benzene metabolites, 
which reflect additional saturable processes 
(see Figure 1). In doing so, we modified the 
usual kinetic formulations in several ways. 
First, we used the metabolite level (Y) as a sur-
rogate for the enzymatic velocity (v) and the 
air concentration of benzene (X) as a surrogate 
for the substrate concentration, recognizing 
that Y and X were not strictly proportional 
to v and the substrate concentration, respec-
tively. Second, it was necessary to include a 
background level (Y0) for total metabolites, to 
account for dietary and endogenous sources 
of these compounds. After fitting Equations 1 
and 2 to the data, we found substantial statis-
tical evidence (AIC difference = 5.473) favor-
ing the model with two metabolic pathways 
(Equation 2). Based on the Akaike weights 
(Equation 3) of 0.939 and 0.061 for the two-
pathway and one-pathway models, respec-
tively, the odds are 15.4 to 1 (0.939/0.061) 
that Equation 2 provides a better depiction of 
true benzene metabolism than does Equation 
1, given these data. The finding is bolstered 
by the independent prediction that a typical 
nonsmoking Chinese female exposed to non-
saturating (parts per billion) levels of benzene 
should produce 194 µM of urinary metabo-
lites per parts per million concentration of 
benzene compared with 184 µM/ppm pre-
dicted under our two-pathway model.
In preliminary analyses, we fit Equation 
2 to the full set of data representing both 
males and females and smokers and non-
smokers (n = 428), after adjustment for age, 
sex, and smoking status (data not shown). 
This led to unrealistically high predicted 
rates of benzene metabolism at low exposure 
levels. Upon further analysis, we attributed 
this result to interaction effects among sex, 
smoking, and the kinetic parameters, notably 
X50,2. Because sex and smoking were highly 
correlated in our Chinese subjects (most of 
the males were smokers and virtually all of 
the females were nonsmokers), we could not 
fully explore the interaction effect(s) and 
therefore focused on nonsmoking females 
where results were unambiguous. Future 
studies should seek to clarify the potential 
interactions of sex, smoking and benzene 
kinetics, using larger numbers of smoking 
and nonsmoking subjects of both sexes.
The affinities of the two metabolic path-
ways are indicated by the Km analogs, desig-
nated X50,1 and X50,2, respectively, in Table 2. 
[Note that factors other than Km can influ-
ence X50,1 and X50,2; see, e.g., Hildebrand 
et al. (1981).] The estimated values of X50,1 
and X50,2 were 301 ppm and 0.594 ppm, 
respectively, indicating a 507-fold differ-
ence in enzyme affinities. Because the high-
affinity metabolic pathway 2 would be 
essentially saturated at a benzene level of 1 
ppm, it is perhaps not surprising that previous 
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toxico-kinetic studies, which relied primarily 
upon data from humans exposed to concen-
trations ≥1 ppm, would have failed to detect 
it (Bois et al. 1996; Travis et al. 1990).
Although our results favor the presence 
of two benzene-metabolizing pathways in 
humans, they provide little insight into the 
identities of the particular enzymes repre-
sented. Because CYP2E1 is the primary 
enzyme responsible for mammalian metabo-
lism of benzene (Koop et al. 1989; Nedelcheva 
et al. 1999; Powley and Carlson 2000), it is 
reasonable to assume that the low-affinity path-
way in our model (pathway 1) is dominated 
by CYP2E1. This conjecture is supported by 
previous analyses of 386 male and female sub-
jects from our study, which showed that the 
homozygous variants of CYP2E1 1054C–T 
(rs2031920, ascribed to RsaI) had significantly 
lower levels of urinary muconic acid, phenol, 
and hydroquinone than did homozygous 
wild types (Kim et al. 2007). Furthermore, 
the ratios of the metabolite levels between 
homozygotes (i.e., variant/variant:wild type/
wild type) became much smaller as benzene 
air concentrations increased above 0.1 ppm, 
suggesting that CYP2E1 1054C–T is active 
primarily at higher concentrations.
Regarding the identity of the high-affinity 
pathway 2, we speculate that this could repre-
sent another CYP enzyme(s). Of the various 
candidates that have been shown to oxidize 
benzene in mammalian in vitro systems, only 
CYP2E1, CYP2B1, and CYP2F1 appear to be 
active in humans, and these have apparent Km 
values in the order 2F1 < < 2E1 < 2B1 (Koop 
et al. 1989; Nedelcheva et al. 1999; Powley 
and Carlson 2000). Thus, although CYP2B1 
could contribute to metabolic pathway 1 
in our model, CYP2F1 could contribute to 
metabolic pathway 2, which operates at low 
benzene concentrations. Powley and Carlson 
(2000) concluded that CYP2F1 is expressed 
in human microsomes from both liver and 
lung and is particularly active in the lung, 
where benzene is absorbed after inhalation. 
Another promising candidate CYP enzyme 
that is worth considering in this context is 
CYP2A13, which is highly expressed in the 
human lung and has recently been shown to 
catalyze several known CYP2E1 substrates, 
namely, toluene, styrene, chlorzoxazone, 
and p-nitrophenol, with much higher affin-
ity compared with CYP2E1 (Fukami et al. 
2008). Thus, CYP2F1 and CYP2A13 should 
be investigated as potential contributors to 
the enhanced benzene metabolism observed 
at air concentrations < 1 ppm.
Because concentrations of benzene in 
ambient air tend to be < 0.01 ppm through-
out the world (Kim et al. 2006a), our results 
suggest that the high-affinity pathway 2 is 
responsible for most metabolism of this air-
borne carcinogen in the general population 
(e.g., about 73% in nonsmoking females; 
Figure 2). Given the potential importance of 
benzene as a source of leukemia and other 
hematopoietic malignancies in the general 
population, it is important that our results 
be independently verified and that the puta-
tive high-affinity pathway 2 be identified. 
Nonetheless, based on the prediction of 184 
µM of benzene metabolites per part per mil-
lion benzene under our two-pathway model 
versus a prediction of 68.6 µM/ppm under 
our one-pathway model, it is reasonable to 
conclude that current risk assessments would 
likely underestimate leukemia risks at ambi-
ent air concentrations of benzene by a factor 
of about 3 for nonsmoking women.
In summary, this study of benzene expo-
sures and metabolite levels among 263 non-
smoking women provides strong statistical 
evidence that an unknown high-affinity path-
way is responsible for most metabolism of 
benzene at sub-part per million air concentra-
tions. Because benzene is a ubiquitous air con-
taminant that must be metabolized in order 
to exert toxicity, our results suggest that the 
metabolism of benzene and its associated leu-
kemia risk could be substantially greater than 
is currently thought in the general population.
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